18 filings
8-K
GALT
Galectin Therapeutics Inc
6 Dec 19
Submission of Matters to a Vote of Security Holders
9:01am
8-K
GALT
Galectin Therapeutics Inc
4 Dec 19
Regulation FD Disclosure
9:26am
8-K
GALT
Galectin Therapeutics Inc
26 Nov 19
Other Events
7:55am
8-K
GALT
Galectin Therapeutics Inc
12 Nov 19
Galectin Therapeutics Reports Q3 2019 Financial Results
7:54am
8-K
GALT
Galectin Therapeutics Inc
27 Sep 19
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
8:30am
8-K
lv3xudw3h
17 Sep 19
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin(GR-MD-02) in Cancer Immunotherapy
7:50am
8-K
wo0cyo7lmp4nt6xj1k7t
9 Aug 19
Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update
7:59am
8-K
tqms 5215pnpiet
5 Aug 19
Other Events
8:00am
8-K
hlt2sy7kumoylcuwpr
28 May 19
Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million From Warrant Exercise
8:55am
8-K
irrw4smzbp16e
10 May 19
Other Events
7:59am
8-K
vjq3ns1
10 May 19
Galectin Therapeutics Reports Q1 2019 Financial Results
7:56am
8-K
7wwdjc8
15 Apr 19
And Expiration Date for Rights Offering and Effectiveness of Its
7:55am
8-K
bpea6bwie9sf0zv5s
21 Mar 19
Regulation FD Disclosure
5:00pm
8-K
h95x7g prp
6 Mar 19
Other Events
7:58am
8-K
ic72gfznnt6et
6 Mar 19
Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
7:55am
8-K
t9kq9f1mc65nl988duki
6 Mar 19
Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
7:55am
8-K
pqruisurvhku xmnnx7v
23 Jan 19
Departure of Directors or Certain Officers
4:31pm
8-K
96kydqowqgww v2pan
15 Jan 19
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years
7:55am
- Prev
- 1
- Next